Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00582257Completed

Early Onset and Familial Gastric Cancer Registry

Role: collaborator

NCT00515411Phase 2Completed

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Role: collaborator

NCT00579696Completed

The Queens Library HealthLink Project

Role: collaborator

NCT01632956Withdrawn

Developing Culturally-Tailored Information-Based Support Groups for Chinese Immigrants With Breast Cancer

Role: collaborator

NCT00933855Completed

Patient Communication Training Intervention

Role: collaborator

All 5 trials loaded